登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
线性分子式:
H2N(CH2)5CO2H
化学文摘社编号:
分子量:
131.17
UNSPSC Code:
12352202
NACRES:
NA.77
PubChem Substance ID:
EC Number:
200-469-3
Beilstein/REAXYS Number:
906872
MDL number:
Assay:
≥99% (titration)
Form:
powder
biological source
synthetic
Quality Level
assay
≥99% (titration)
form
powder
technique(s)
cell culture | mammalian: suitable
color
white
mp
207-209 °C (dec.) (lit.)
solubility
H2O: 50 mg/mL
SMILES string
NCCCCCC(O)=O
InChI
1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)
InChI key
SLXKOJJOQWFEFD-UHFFFAOYSA-N
Gene Information
human ... PLAT(5327), PLG(5340)
rat ... Ppm1a(24666)
Application
EAC以25mg/ml溶解于水。因为是纤溶酶抑制剂,它被用在纤维蛋白酶分析凝血缓冲液。缓冲液是10mM磷酸钾和磷酸钠,pH6.4,再加上0.20gCaCl2, 5g 6-氨基己酸,1g叠氮化钠和9g氯化钠,都溶解在1升体系里。缓冲液在室外下无限期稳定。
Biochem/physiol Actions
EACA被报道能够抑制糜蛋白酶、因子VIIA、赖氨酸碳氧基肽酶、纤溶酶,纤溶酶原激活物。
赖氨酸类似物。促进纤溶酶的快速解离,从而抑制纤溶酶原的活化和随后的纤维蛋白溶解。
赖氨酸类似物。促进纤溶酶的快速解离,从而抑制纤溶酶原的活化和随后的纤维蛋白溶解。据报道可抑制纤溶酶原与活化的血小板结合。 早期报告表明,它抑制补体系统第一成分的激活。结合羧肽酶 B并使其灭活。
Still not finding the right product?
Explore all of our products under 6-氨基己酸
存储类别
11 - Combustible Solids
flash_point_f
404.6 - 408.2 °F
flash_point_c
207 - 209 °C
ppe
dust mask type N95 (US), Eyeshields, Gloves
商品
Analytical Enzyme Chymotrypsin: Chymotrypsin is produced in the acinar cells of the pancreas as the inactive precursor, chymotrypsinogen.
Kazuki Yamamoto et al.
Lab on a chip, 21(10), 1897-1907 (2021-05-20)
Engineered three-dimensional models of neuromuscular tissues are promising for use in mimicking their disorder states in vitro. Although several models have been developed, it is still challenging to mimic the physically separated structures of motor neurons (MNs) and skeletal muscle
E M Van Hoeyveld et al.
The Journal of allergy and clinical immunology, 76(4), 543-550 (1985-10-01)
The effect of epsilon-aminocaproic acid (EACA) on the degradation of an aqueous Lolium perenne extract was studied by intracutaneous tests and by RAST inhibition. Extracts for skin testing stored at 4 degrees C for 12 months and at 37 degrees
Brian Hutton et al.
BMJ (Clinical research ed.), 345, e5798-e5798 (2012-09-13)
To estimate the relative risks of death, myocardial infarction, stroke, and renal failure or dysfunction between antifibrinolytics and no treatment following the suspension of aprotinin from the market in 2008 for safety reasons and its recent reintroduction in Europe and
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| A2504-500G | 04061833350355 |
| A2504-5KG | 04061832938813 |
| A2504-100G | 04061833350331 |
| A2504-1KG | 04061826740866 |
| A2504-25G | 04061833350348 |